Amount of eligible individuals: CDEC mentioned the uncertainty in the number of sufferers with reasonably serious to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who are categorized as having mild or moderate condition might have a serious bleeding phenotype, https://cullens246prs9.wikicommunications.com/user